Hypogonadism - A Pipeline Analysis Report

Overview of the drug development pipeline for hypogonadism

Hypogonadism refers to a condition when there is less or no secretion of the sex hormones, leading to various changes in the secondary sexual characteristics. Secondary sexual characteristics include breast development in females and testicular development in males. Therefore, the production of sex hormones affects the menstrual cycle and sperm production. The glands that produce the sex hormones are known as gonads. Hence, hypogonadism is also termed as gonad deficiency. As per NIH, hypogonadism is largely seen in middle-aged and older-aged individuals. The incidence of hypogonadism increases with age. Furthermore, according to NIH, there is an increase in the number of people aged 65 years and above in the US. The number of people who belong to the above-mentioned age groups is expected to increase to 60 million in 2025 from 40 million, which may result in an increase in the incidences of hypogonadism. As a result, the increasing incidences of hypogonadism is expected to boost the drug development for hypogonadism during the upcoming years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for male hypogonadism. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hypogonadism. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Acerus Pharmaceuticals
• Antares Pharma
• Diurnal
• Endoceutics
• Ferring

Therapeutic assessment of the drug development pipeline for hypogonadism by route of administration

• Nasal
• Oral
• Subcutaneous
• Topical
• Transdermal

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for hypogonadism by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for hypogonadism are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for hypogonadism?
• What are the companies that are currently involved in the development of drug molecules for hypogonadism?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.